Printer Friendly

AnGes MG, Seikagaku to Dissolve Joint Development Agreement for NFkB Decoy-Oligo-based Intraarticular Injection.

Tokyo, Japan, Feb 6, 2006 - (JCN) - AnGes MG and Seikagaku jointly announced on February 3 that they have agreed to dissolve their agreement on joint development of NF-kappa B decoy oligodeoxynucleotide (NFkB decoy-oligo).

Since August 2002, the two companies have been collaborating in the development of intraarticular injection for treating rheumatism and osteoarthritis.

After evaluating the validity of their joint development efforts, Seikagaku has decided to withdraw from the development project. In the meantime, AnGes MG plans to continue the development of an NFkB decoy-oligo-based intraarticula injection.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Feb 7, 2006
Words:97
Previous Article:Fuji Heavy Industries to License Lithium Ion Capacity Technology to Nihon Micro Coating.
Next Article:Nippon Milk Community to Bring to Market New Probiotic Yogurt Series.


Related Articles
AnGes MG to Start Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.
AnGes MG, Avontec Enter into Cross Licensing Agreement for Decoy Nucleic Acid Drug.
AnGes MG Finally Starts Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.
Hosokawa Micron, AnGes MG Succeed in Creating Composite Nanoparticle Contating NF-Kappa B Decoy Oligodeoxynucleotide.
AnGes MG, Osaka University, Aoki Undertake Co-development of Fully Bioabsorbable Stent.
AnGes MG Registers 9th Case of Phase I Clinical Trial for HGF Gene Medicine Conducted in US.
AnGes MG, FALCO biosystems to Form Business Alliance in Gene Therapy Business.
AnGes MG, Vical to Collaborate in Developing Genomic Drug for Skin Cancer.
AnGes MG Unveils Future Development Strategies for HGF Gene Medicine.
Seikagaku to Begin Clinical Trials of Injectable Hyaluronic Acid Gel for Knee Osteoarthritis Treatment in US.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |